[Gastrointestinal stromal tumors : Where do we stand?]

Eva Wardelmann1, Anna Kuntze2, Artem Voloshin2

  • 1Gerhard-Domagk-Institut für Pathologie, Universitätsklinikum Münster, Albert-Schweitzer-Campus 1, 48149, Münster, Deutschland. eva.wardelmann@ukmuenster.de.

Summary

Molecular typing of gastrointestinal stromal tumors (GIST) is crucial for targeted therapy with tyrosine kinase inhibitors. Considering hereditary predispositions impacts treatment and follow-up strategies for GIST patients.

Related Concept Videos